Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

← catalyst calendar

NCT04064827 · results posted

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase
Phase 3
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
2actual
Sites
15
Countries
Puerto Rico, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

Company Decision

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2020-09-16actualWhen the study began enrolling
Primary completion2025-06-09actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-06-09actualThe whole study's end, after follow-up
First posted2019-08-22actualWhen this record first appeared on the registry
Results posted2026-06-15actualWhen the sponsor posted results to the registry
Record updated2026-06-15actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Chronic Kidney Disease (CKD)
  • Secondary Hyperparathyroidism (SHPT)

Intervention

  • Drug: Paricalcitol

Primary outcomes

what the primary-completion date above is the date OF
Percentage of Participants Who Achieve Positive Response During Dosing Period 1
measured Up to Week 12
Incidence of Hypercalcemia During Dosing Period 1
measured Up to Week 12

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2023-07-13 · 901 KB · Prot_000.pdf
Statistical Analysis Planposted 2025-11-07 · 544 KB · SAP_001.pdf

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed